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a  b  s  t  r  a  c  t
At  the age  of  7–8 years  a booster  of diphtheria,  tetanus,  acellular  pertussis  and  polio  vaccine  is  recom-
mended  for children  in Norway.  In this  cross-sectional  study  we  have  analysed  the antibody  levels  against
pertussis  vaccine  antigens  in sera  from  498  children  aged 6–12  years.  The  purposes  of this  study  were
to  investigate  the duration  of the booster  response  against  the  pertussis  vaccine  antigens  pertussis  toxin
(PT)  and  ﬁlamentous  haemagglutinin  (FHA);  to determine  the presence  of high  levels  of  pertussis  anti-
bodies  in absence  of recent  vaccination;  and  to analyse  how  booster  immunisation  may  interfere  with
the  serological  pertussis  diagnostics.  Prior  to the booster  the  IgG  antibody  levels  against  PT  revealed  a
geometric  mean  of 7.3 IU/ml.  After  the  booster  the  geometric  mean  peak  anti-PT  IgG  response  reached
to  45.6  IU/ml,  followed  by a steady  decline  in antibody  levels  over  the  next  few  years.  The  IgG  anti-FHA
levels  followed  the  anti-PT  IgG  proﬁles.  Three  years  after  the  booster  the  geometric  mean  IgG levels  were
only slightly  above  pre-booster  levels.  Prior  to  the  booster  44% of  the sera  contained  ≤5  IU/ml  of  anti-PT
IgG  compared  to18%  3 years  after  and  30%  4 years  after  the  booster.  When  recently  vaccinated  children
were  excluded,  6.2%  of the children  had  anti-PT  IgG levels  above  50 IU/ml  which  may  indicate  pertussis
infection  within  the  last  2  years.  This  study  indicates  that  the currently  used  acellular  pertussis  vac-
cines  induce  moderate  immune  responses  to the pertussis  antigens  and  that  the  antibodies  wane  within
few  years  after the  booster.  This lack  of  sustained  immune  response  may  partly  be responsible  for  the
increased  number  of pertussis  cases  observed  in  this  age  group  during  the  last  years.
ublis©  2014  The  Authors.  P
. Introduction
Many countries experience increasing incidences of pertussis in
pite of a high vaccine coverage [1]. The reasons for this increase
re multifactorial as improved diagnostics, increased awareness,
emographic changes, genetic adaptation of the causative bacte-
ia Bordetella pertussis and vaccine failure, all may  contribute [1,2].
he resurgence seems to coincide with the shift from the use of
hole cell (wP) to acellular pertussis (aP) vaccines [3] although
any clinical studies of aP and wP vaccines indicate that both types
f vaccines induce comparable immunity [4,5]. However, studies
omparing aP and wP vaccination that depend on immunogenic-
ty data and non-inferiority criteria of antibody levels measured
gainst the aP vaccine antigens rather than efﬁcacy studies, must
e interpreted with care as such studies may  favour the aP vaccines.
∗ Corresponding author.Tel.: +47 21076662; fax: +47 22353605.
E-mail address: audun.aase@fhi.no (A. Aase).
ttp://dx.doi.org/10.1016/j.vaccine.2014.08.069
264-410X/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article unhed  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
More recent studies suggest that the duration of protection follow-
ing DTaP immunisation in the ﬁrst year of life is lower than with
DTwP [1,6–8].
Norway has been one of the countries with the highest num-
ber of reported pertussis cases in Europe, in spite of approximately
95% vaccination coverage. The incidence has been particularly high
in the age groups 5–19 years. From 1998, a DTaP vaccine contain-
ing three-component pertussis antigens has been implemented in
a three dose regimen at 3, 5 and 12 months in the ﬁrst year of life
instead of the DTwP vaccine. In 2006 a two-component pertussis
DTaP booster to children at the age of 7–8 years was implemented
in the Childhood Immunisation Program. This resulted in a drop
in the incidence of pertussis particularly within the immunised
group. However, previous studies indicate that the decay of anti-
bodies against pertussis antigens both after primary and booster
immunisation is rapid [9–12].
High anti-pertussis toxin (PT) IgG levels in the absence of recent
vaccination may  be used as a diagnostic test for recent or active
pertussis [13]. The use of serology with detection of high levels of
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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nti-PT IgG may  thus be a valuable tool for the diagnosis of pertussis
ven though polymerase chain reaction (PCR) now becomes more
idespread in use and about 60% of recorded cases in Norway in
012 were based on PCR. On the other hand, vaccination against
ertussis in different age groups may  complicate interpretation of
erological diagnosis, particularly if the vaccine induced antibody
evels are high. It is recommended not to use serology for diagnosis
ithin the ﬁrst 2 years after pertussis immunisation [14].
We have performed a cross-sectional study to measure the anti-
ody immune response against pertussis in 498 children aged 6–12
ears who were scheduled to receive a DTaP booster vaccine at the
ge of 7–8 years. The aim of the current work was to study the
uration of the booster response against the different pertussis vac-
ine antigens; to determine the proportion of high antibody levels
n absence of recent vaccination thus reﬂecting recent infection;
nd to analyse how booster immunisation may  interfere with the
erological diagnosis.
. Materials and Methods
.1. Serum sample collection
Serum samples from 503 children submitted to the laboratory
t the Department of clinical biochemistry for analysis at Aker-
hus University Hospital from December 2009 to January 2011
ere collected. They were leftover volumes after clinical biochem-
stry analysis and were randomly picked out during the 14 months
eriod. The children were born between 1998 and 2003 and were
cheduled to have a DTaP-polio booster vaccination at the age of
–8 years. Approximately half of the samples (46%) were from gen-
ral practitioners (GPs), the rest were from in-patients. One third of
he samples from the GPs lacked any information regarding diag-
osis and medical records were not available. Medical records were
hecked for all in-patients, leading to the exclusion of ﬁve patients
uffering from diagnoses likely to cause immunodeﬁciency (acute
ymphatic leukaemia, lymphoma, former spleen extirpation). The
wo dominating indications for sampling were allergy investiga-
ion and acute infection, followed by unspeciﬁed stomach pain,
eurological/psychiatric disease and endocrine disorders. A total of
98 children were thus included. Date of blood sampling and date
f birth and personal identiﬁcation number for each person were
ecorded, and linked to the Norwegian Immunisation Registry (SYS-
AK) to obtain the vaccine history and to calculate the number of
ays between last pertussis booster and blood sampling. The study
as approved by the Norwegian Regional Committee for Medical
esearch Ethics.
.2. Vaccination
The childhood pertussis vaccination program in Norway con-
ists of three doses of DTaP-polio at 3, 5 and 12 months of age,
ontaining the pertussis antigens pertussis toxoid, ﬁlamentous
aemagglutinin (FHA) and pertactin (Prn) (Infanrix-polio, GSK). At
he age of 7–8 years the children are offered a booster dose con-
isting of pertussis toxoid and FHA (Tetravac, Sanoﬁ Pasteur MSD).
.3. Serological analysis
Anti-PT IgG antibodies were analysed using a validated in-house
nzyme-linked immunosorbent assay (ELISA) slightly modiﬁed
rom previous publications [15,16]. Brieﬂy, PT (List Biological labs,
A, USA) was coated to 96 wells micro-titer plates at 1 g/ml in
.05 M bicarbonate buffer pH 9.6 for 48 h at 4 ◦C. Blocking was  per-
ormed with 250 L 1% powdered skimmed milk (Oxoid, UK) in
BS for 30 min  at room temperature. Two-fold serial dilutions of
atients sera were analysed, and bound antibody was detected with(2014) 5931–5936
an anti-human IgG (gamma  chain-speciﬁc) alkaline phosphatase
conjugate (Sigma, USA). The WHO  International Standard Pertussis
Antiserum (NIBSC 06/140) was  used to generate the standard curve.
Interpolation of unknown sera was  done by four-parameter curve
analysis (Softmax Ver. 2.35, Molecular Devices Corp., UK). Values
from at least two dilutions showing parallelism to the standard
curve were used to calculate the IgG level, expressed as IU/ml. The
lower limit of detection was  1 IU/ml, and sera with values below
this were assigned a value of 1 IU/ml.
IgG antibodies against pertactin (Prn) (RIVM, the Netherlands)
were measured with a similar method as for the anti-PT IgG, with
a Prn coat at 1 g/ml [17]. The sera were diluted in four two-fold
dilutions and the results were calculated against the WHO  refer-
ence serum 06/140, containing 65 IU/ml anti-Prn IgG by the use of
four-parameter curve analysis.
IgG antibodies against FHA were analysed using Pertusscan
2 + 2 (Euro-Diagnostica AB, Malmö, Sweden), and the results were
reported as a percentage of the negative cut-off (i.e., an optical
density of 0.3 equals 100%). This is the preferred kit to measure
anti-FHA IgG by the Norwegian diagnostic laboratories. The per-
formance was according to manufacturer’s instruction and one
dilution (1:500) of test sera was  used in the analysis.
In-house positive control serua were included in all ELISA
plates and demonstrated good reproducibility of the assays, with
a coefﬁcient of variation of <10% for the anti-PT IgG, 16% for the
anti-FHA-IgG, and 17% for the anti-PRN-IgG.
2.4. Statistical analysis
The sera were grouped into three subsets: sera from subjects
who had received the booster dose at scheduled time (booster
group), sera from subjects who had not received the booster (pre-
booster group), and sera from subjects who  had no recorded
pertussis vaccine history. Linear regression analysis was used to
assess the relationship between antibody levels and time since
booster dose. The sera in the booster group were congregated into
groups of 100 days after booster vaccination. Geometric mean (GM)
levels and 95% conﬁdent intervals (CI) of GM were determined for
IgG antibodies against the pertussis antigens PT, FHA and Prn for all
groups. Anti-PT IgG ≤5 IU/ml was  used as a measure of low speciﬁc
antibody level.
3. Results
3.1. Immunisation history
The vaccination history of the 498 children is summarised in
Table 1. According to the immunisation register 485 individuals
(97%) had received three doses in the primary immunisation series
during their ﬁrst year of life. Of the patients born in the years from
1998 to 2002, 89% had received the fourth booster dose according
to schedule at the age of 6–8 years. The patients born in 2003 had
not yet been offered the booster dose. Thirteen children had no
recorded vaccine history.
3.2. Antibody decay after booster
Fig. 1 shows the individual serum IgG levels against PT, FHA
and Prn plotted against time since the booster dose (red circles) or
since the primary immunisation series (blue triangles). Previous to
the booster, the GM anti-PT IgG level was  7.3 IU/ml (95% CI: 6.0,
9.0 IU/ml) of the 104 participants who had only received the pri-
mary immunisations. As expected, the PT and FHA levels increased
following the booster dose and were highest in the sera from those
most recently immunised, with a peak anti-PT IgG GM level of
45.6 IU/ml (95% CI: 24.8, 83.9 IU/ml) and a peak anti-FHA IgG GM
A. Aase et al. / Vaccine 32 (2014) 5931–5936 5933
Table  1
Pertussis immunisation history of the 498 participants included (number of children in each birth year).
Vaccine history 1998 1999 2000 2001 2002 2003
Primary vaccination 94 92 92 74 67 66
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evel of 336.6 AU/ml (95% CI: 284.3, 398.6 AU/ml) within the ﬁrst
00 days after the booster (Fig. 2A and B). After the peak response,
here was a steady decline in anti-PT and anti-FHA IgG levels. But
ven in the samples collected 1001–1745 days after the 4th booster,
he anti-PT- and anti-FHA IgG levels were still signiﬁcantly higher
P < 0.05) than in sera collected before the booster (Fig. 2A and B).
he anti-PT IgG GM levels from samples collected within the ﬁrst
ear post booster was 32.3 IU/ml (95% CI: 25.6, 40.8 IU/ml), and 33%
f these sera had an anti-PT IgG level ≤20 IU/ml. The number of
era with anti-PT IgG levels ≤5 IU/ml increased with time since the
ooster. The ﬁrst 300 days after the booster, none of the sera con-
ained an anti-PT IgG level ≤5 IU/ml (Fig. 3), whereas from 300 to
000 days after the booster 14–16% of the samples displayed levels
5 IU/ml and from 1000 to 1745 days even 18–30%. Of the 104 sub-
ects who had not received the booster dose, 43% had an anti-PT IgG
evel ≤5 IU/ml (6.4 geometric mean years since previous (primary)
ertussis vaccination of the whole group).
According to the records from SYSVAK, 13 subjects had not
eceived any pertussis vaccine ever. The GM anti-PT IgG level for
his group was 11.8 IU/ml (95% CI: 6.0, 23.2), and 31% had an anti-PT
gG level ≤5 IU/ml (Fig. 3).
The vaccine used for booster at 7–8 years contains only the per-
ussis antigens PT and FHA; consequently there was  no increase in
he anti-Prn IgG level after the booster (Figs. 1C and 2C). Although
here seemed to be an increase in anti-Prn IgG levels in the years
ollowing the booster (Fig. 1C red circles), no signiﬁcant difference
ould be observed between the sera collected within the ﬁrst 365
ays and the sera collected 1101 to 1745 days after the booster. The
nti-Prn IgG GM level of the whole booster group was  25.1 IU/ml
CI: 22.5, 28.1 IU/ml) and for the pre-booster group 22.0 IU/ml (CI:
8.5, 26.3 IU/ml).
.3. High anti-PT IgG and anti-Prn IgG as markers for recent
ertussis
A high level of anti-PT IgG in absence of recent vaccination
s used as indication of recent pertussis. For seroepidemiological
tudies an anti-PT IgG cut-off of 80 IU/ml may  be used to iden-
ify pertussis infection within the last year, whereas a cut-off of
0 IU/ml may  indicate infection within the last two years [18]. Anal-
sis of sera from patients, who had not been vaccinated within the
ast 2 years, revealed that 6 of 369 sera (1.6%) had anti-PT IgG levels
ig. 1. Individual IgG levels against pertussis toxin (PT)(A), ﬁlamentous haemagglutinin
ose  as age 7–8 years (red circles), or since primary immunisation (no 4th dose) (blue tria
nterpretation of the references to colour in this ﬁgure legend, the reader is referred to th85 66 51 0
2 2 1 3
94 76 68 69
higher than the recommended Norwegian cut-off of 80 IU/ml, and
23 sera (6.2%) were above 50 IU/ml.
Since the vaccine used at this age does not contain Prn, high
levels of anti-Prn IgG might indicate recent infection. Forty-nine
of the 498 sera (10%) displayed an anti-Prn IgG level ≥100 IU/ml
and 39 of these subjects had not been immunised within the last 2
years. Two sera with anti-Prn IgG levels >100 IU/ml also had anti-
PT IgG higher than 80 IU/ml; one had been boosted 573 days ago
and the other one with anti-PT IgG of 505 IU/ml and anti-Prn IgG of
175 IU/ml had been immunised only 18 days earlier.
In Norway a diagnostic cut-off of anti-PT IgG level at 80 IU/ml is
recommended (established with the Virion\Serion Bordetella Per-
tussis Toxin IgG assay). Within the ﬁrst 2 years after the booster only
9 of 130 subjects had anti-PT IgG values above this level; however,
4 of these also had an anti-Prn IgG level above 50 IU/ml possibly
indicating recent infection with B. pertussis.
4. Discussion
Antibodies against pertussis vaccine antigens were measured
in a cross-sectional study in sera from children aged 6–12 years.
Most of the children received a DTaP booster vaccine at age 7–8
years. At 6.4 geometric mean years after primary vaccination, the
pre-booster anti-PT IgG GM level was  7.3 IU/ml. In the ﬁrst 100
days after the booster dose a rather moderate peak response was
observed reaching up to an anti-PT IgG GM level of 45.6 IU/ml,
which was  followed by a subsequent decline the following years.
Three years after the booster dose almost 20% of the sera contained
an anti-PT IgG level less than 5 IU/ml.
These anti-PT IgG levels are lower than the corresponding lev-
els reported in a Danish study where adults were given a booster
vaccine with a single-component pertussis antigen (PT), in spite of
the lower PT-antigen content in the Danish vaccine [10]. Also, in
a Dutch study using an aP booster vaccine with a similar dose of
PT and FHA [19], higher anti-PT IgG levels (187 EU/ml 28 days post
booster) were found than we  did in our study. The shorter inter-
val between primary immunisation series and the booster dose
in the Dutch study (4 years versus 6 years) and the shorter and
exact blood sample timing after the booster (28 days versus 0–100
days (mean 59 days)) might possibly explain the more pronounced
booster response. In line with our results they also noted a sig-
niﬁcant decline in the anti-PT IgG level 2 years after the booster.
 (FHA)(B), and pertactin (Prn)(C) in sera from 485 subjects and days since booster
ngles). The straight lines represent the linear regression lines of each data set. (For
e web version of this article.)
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Fig. 2. Geometric mean and 95% CI of IgG antibody levels against PT (A), FHA (B), and
Prn (C) and days since last DTaP-booster (4th dose). The stippled line in A indicates
the non-linear ﬁt against the geometric mean of the booster group. (“Pre-booster”
means that no DTP vaccine has been recorded since the primary immunisation, and
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Fig. 3. Proportion of samples with anti-PT IgG ≤5 IU/ml and number of days since
last DTP. The ﬁgures above the X-axis show the total number of sera in each aggre-
About 10% of the sera revealed anti-Prn IgG levels >100 IU/ml.
Such high anti-Prn IgG levels may  be a result of the primary immu-
nisations 6–11 years earlier, but this seems unlikely considering
Fig. 4. The incidence of pertussis in the years 2009 to 2012 as notiﬁed to the Norwe-
gian Surveillance System for Communicable Diseases (MSIS). A booster DTaP startedNo vaccine” means that no DTP vaccine is recorded ever.).
aution should nevertheless be taken when results from different
aboratories are compared; however the methods used are simi-
ar and have been compared through inter-laboratory evaluations.
he differences observed are more likely explained by different vac-
ine history, different vaccines, different age groups, and possible
nterference from other vaccine antigens.In line with the decrease of pertussis-speciﬁc antibodies, a
igher number of sera with an anti-PT IgG level ≤5 IU/ml were
ound with increasing time since booster. Although there is no
stablished serological correlate of protection against pertussis, itgated group (total of 498 samples). (The ﬁrst three groups contain 0% with anti-PT
IgG  ≤5 IU/ml.).
is likely that subjects with low vaccine-induced anti-PT IgG lev-
els are less protected than subjects with higher levels [20,21]. This
is also supported by data from the Norwegian Surveillance Sys-
tem for Communicable Diseases that show a peak in the incidence
of pertussis at 6 year of age (prior to the booster), followed by a
drop after the booster at age 7–8 years, and a subsequent large
increase from the age of 11 to 15–16 years (Fig. 4) (Statistics from
the Norwegian Surveillance System for Communicable Diseases,
MSIS, Norwegian Institute of Public Health: http://www.msis.no/).
It must be emphasised that the booster DTaP vaccine at age 7–8
years was  implemented in 2006, and that the increase observed
within the 11–15 years olds, most likely relates to individuals that
were too old to have received this booster. However, the incidence
ﬁgures from 2012 show an increased incidence starting already at
the age of 10 years, i.e. in subjects who most likely have achieved
the booster vaccine. These data thus indicate that the booster
introduced in 2006 only protects for about 3–4 years. This is com-
parable to what have been observed in other countries recently
[22,23].in  2006 to 7–8 year old children, hence, the increased incidence seen between 11
and  15 years of age is of children that for the most were too old to have got the
booster at age 7–8 years. The curves of the year 2011 and 2012 indicate that the
booster only protects for about 3–4 years.
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he rapid waning of pertussis speciﬁc antibody levels after vacci-
ation [19]. This proportion of high Prn antibody levels can better
e explained by infection with circulating Prn-expressing strains
ike B. pertussis or Bordetella parapertussis [24]. However, there was
o signiﬁcant correlation between the level of IgG against Prn and
T in these sera with high anti-Prn IgG. Prn is a very immunogenic
ntigen that readily gives rise to high antibody levels which may
ast for a long time [25,26]. Also, PRN antibodies might be induced
arlier in infection and prevent disease, while PT antibodies are
ater induced in infection and after early signs of disease. Conse-
uently, antibodies against Prn cannot be used to diagnose active
ertussis, at least not from a single serum sample. Of importance in
his regard is also the high frequency of circulating Prn-negative
. pertussis strains that have been observed in many countries
ecently [27,28]. In Norway around 20% of the analysed isolates
rom the last 5 years were found to be Prn-negative (unpublished
bservations).
For serological diagnostics, we have recommended a cut-off at
0 IU/ml in absence of recent vaccination. Only 9 of 130 sera (7%)
ad anti-PT IgG above this level within the two ﬁrst years after
he booster, and 6 of these samples were collected within the ﬁrst
ear after the booster and thus most likely vaccine induced. This
ndicates that booster immunisation with aP vaccine interferes
arginally with serological diagnostic, as previously described by
thers [12,14].
A limitation of this study might be that the sera were randomly
icked from leftovers volumes of samples for clinical chemistry
nalysis. They were thus not from healthy children but rather from
hildren under evaluation for different diseases/illnesses. It may
hus be argued that such left-over sera may  not be representative
or the general population regarding the immune response against
ertussis following infection or vaccination. However, the peak
esponse observed in this study is very similar to what we observed
n a previous vaccine study [17] Such left-over samples are often
sed for these kinds of studies, as in a recent seroprevalence study
f pertussis involving sixteen European countries (Organization
f a sereoprevalence study of pertussis in the member states and
EA countries (WP6); Speciﬁc Contract ECDC/2011/013). Sera from
hildren where the medical record indicated possible immunode-
ciency were excluded.
Another limitation may  be associated to the reported pertus-
is incidence peak in 2009 compared to the next years. This may
ave caused an increased transmission of pertussis during the ﬁrst
onths of collection. However, when the average anti-PT IgG lev-
ls were compared among sera collected at the start of the project
ith sera collected at the end of the project no differences were
een (data not shown).
In conclusion our data indicate that the immunity against
ertussis is low 5 years after primary vaccination and that the
TaP-booster administered at age 7–8 years gives a moderate anti-
ertussis immune response that wanes to near pre-booster level
n a few years. This sero-epidemiological study contributes to the
onclusion that some, if not all, of the aP vaccines are inadequate
o reduce the burden of pertussis. Although serious disease in the
mallest, most vulnerable, not completely vaccinated children still
s rare due to mass vaccinations with aP, improved pertussis vac-
ines are needed. Improved vaccines should leave a longer-lasting
mmune response and should also harbour additional antigens that
inimise the problems with vaccine escape mutant B. pertussis
trains.cknowledgements
We gratefully acknowledge Samuel Merino at the Norwegian
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